Endothelins in cardiovascular biology and therapeutics
Open Access
- 13 March 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Cardiology
- Vol. 16 (8), 491-502
- https://doi.org/10.1038/s41569-019-0176-3
Abstract
Cardiovascular disease is a major contributor to global morbidity and mortality and is the common end point of many chronic diseases. The endothelins comprise three structurally similar peptides of 21 amino acids in length. Endothelin 1 (ET-1) and ET-2 activate two G protein-coupled receptors — endothelin receptor type A (ETA) and endothelin receptor type B (ETB) — with equal affinity, whereas ET-3 has a lower affinity for ETA. ET-1 is the most potent vasoconstrictor in the human cardiovascular system and has remarkably long-lasting actions. ET-1 contributes to vasoconstriction, vascular and cardiac hypertrophy, inflammation, and to the development and progression of cardiovascular disease. Endothelin receptor antagonists have revolutionized the treatment of pulmonary arterial hypertension. Clinical trials continue to explore new applications of endothelin receptor antagonists, particularly in treatment-resistant hypertension, chronic kidney disease and patients receiving antiangiogenic therapies. Translational studies have identified important roles for the endothelin isoforms and new therapeutic targets during development, in fluid-electrolyte homeostasis, and in cardiovascular and neuronal function. Novel pharmacological strategies are emerging in the form of small-molecule epigenetic modulators, biologics (such as monoclonal antibodies for ETB) and possibly signalling pathway-biased agonists and antagonists.Keywords
This publication has 109 references indexed in Scilit:
- Gestational Hypoxia Induces Preeclampsia-Like Symptoms via Heightened Endothelin-1 Signaling in Pregnant RatsHypertension, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Acute kidney injury: an increasing global concernThe Lancet, 2013
- Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic NephropathyJournal of the American Society of Nephrology, 2011
- Role of Endothelin in Mediating Soluble fms-Like Tyrosine Kinase 1–Induced Hypertension in Pregnant RatsHypertension, 2010
- Avosentan Reduces Albumin Excretion in Diabetics with MacroalbuminuriaJournal of the American Society of Nephrology, 2009
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008
- Clinical trials of endothelin antagonists in heart failure: publication is good for the public healthHeart, 2007
- Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retentionAmerican Journal of Physiology-Renal Physiology, 2006
- Endothelin up-regulation and localization following renal ischemia and reperfusionKidney International, 1999